PROCYON CORP
PCYN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PCYN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PCYN
Procoyn Corp (PCYN) is a company that has expanded its product line and services, including the introduction of a new Rolled Gauze form of its Amerx brand and a new website for its Extremit-Ease product, while facing ongoing operational risks and uncertainties.
Key risk: COVID-19 impact on operations
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.0M
Cash Runway
—
Lead Asset
helix3 bioactive collagen (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2024.
Tracking 1 pipeline candidate for PROCYON CORP.
Procoyn Corp (PCYN) is a company that has expanded its product line and services, including the introduction of a new Rolled Gauze form of its Amerx brand and a new website for its Extremit-Ease product, while facing ongoing operational risks and uncertainties.
- Introduced a new Rolled Gauze form of its Amerx collagen line [sec_mda · as of 2024-05-24].
- Created a new website for the Extremit-Ease product (www.extremitease.com) [sec_mda · as of 2022-05-11].
- Expanded facilities in January 2021, moving into approximately 18,000 square feet [sec_mda · as of 2022-05-11].
- Shareholders' equity of $2.6M as of 2024-06-30 [sec].
- Net income of $0.0M as of 2024-06-30 [sec].
What works
- The company has expanded its product offerings, including a new Rolled Gauze form of its Amerx collagen line, indicating ongoing product development [sec_mda · as of 2024-05-24].
- Management has been working on new Business to Customer (B to C) channels to provide retail customers better opportunities to purchase products, potentially expanding market reach [sec_mda · as of 2022-05-11].
What to weigh
- The company faces risks and uncertainties related to the COVID-19 pandemic on sales, operations, and supply chain [sec_mda · as of 2024-05-24].
- Forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially [sec_mda · as of 2024-05-24].
- Shareholders' equity is relatively low at $2.6M as of 2024-06-30, indicating a small capital base [sec].
From the filings
Quoted directly from source documents.
Introduction of new Rolled Gauze form of Amerx collagen line
“Amerx expanded our collagen line with the introduction o”
SEC MD&A · May 24, 2024
New website for Extremit-Ease product
“A new website for the Extremit-Ease product was created and is operational (www.extremitease.com).”
SEC MD&A · May 11, 2022
Facility expansion in January 2021
“The Company also expanded its facilities in January 2021, moving into approximately 18,000 square feet of”
SEC MD&A · May 11, 2022
Risks & what to watch (3)›
Key risks
- COVID-19 impact on operations — The pandemic may affect sales, operations, and supply chain [sec_mda · as of 2024-05-24].
- Forward-looking statement uncertainties — Actual results could differ materially due to risks and assumptions [sec_mda · as of 2024-05-24].
- Low shareholders' equity — Shareholders' equity of $2.6M as of 2024-06-30 indicates a small capital base [sec].
What to watch
- Monitor the impact of new product introductions (e.g., Rolled Gauze) on revenue [sec_mda · as of 2024-05-24].
- Watch for updates on the B to C channel development and its effect on retail sales [sec_mda · as of 2022-05-11].
- Track any further facility expansions or operational changes [sec_mda · as of 2022-05-11].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run PROCYON CORP through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROCYON CORP facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.40
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for PROCYON CORP?
Procoyn Corp (PCYN) is a company that has expanded its product line and services, including the introduction of a new Rolled Gauze form of its Amerx brand and a new website for its Extremit-Ease product, while facing ongoing operational risks and uncertainties.
What is PROCYON CORP's lead drug candidate?
PROCYON CORP's most advanced tracked candidate is helix3 bioactive collagen (Approved) for wound care.
Who is the CEO of PROCYON CORP?
Mr. Justice W. Anderson is the chief executive officer of PROCYON CORP (PCYN).
Where is PROCYON CORP headquartered?
PROCYON CORP (PCYN) is headquartered in Oldsmar, FL, United States.
What therapeutic areas does PROCYON CORP focus on?
PROCYON CORP develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.